图片来源:摄图网
近日,港股上市公司德琪医药发布公告称,与翰森制药达成独家合作协议,由翰森制药负责塞利尼索在中国大陆的商业化, 德琪医药将获最高2亿元首付款及最高5.35亿元里程碑付款。
据了解,塞利尼索是德琪医药首个上市商业化产品,从Karyopharm引进,...查看全文
$Karyopharm(KPTI)$ SC 13G Statement of acquisition of beneficial ownership by individuals Accession Number: 0000902664-20-001123 Act: 34 Size: 66 KB 网页链接
$Karyopharm(KPTI)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0001193125-20-035536 Act: 34 Size: 66 KB 网页链接
$Karyopharm(KPTI)$ SC 13G Statement of acquisition of beneficial ownership by individuals Accession Number: 0000093751-20-000445 Act: 34 Size: 8 KB 网页链接
$Karyopharm(KPTI)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0001193125-20-034173 Act: 34 Size: 289 KB 网页链接
$Karyopharm(KPTI)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-20-008727 Size: 15 KB 网页链接
$Karyopharm(KPTI)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-20-008729 Size: 15 KB 网页链接
$Karyopharm(KPTI)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0000902664-20-000963 Act: 34 Size: 100 KB 网页链接
$Karyopharm(KPTI)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-20-007510 Size: 8 KB 网页链接
$Karyopharm(KPTI)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-20-007514 Size: 8 KB 网页链接
$Karyopharm(KPTI)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-20-007515 Size: 8 KB 网页链接